BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced it will present early safety and efficacy data for ...
BRIDGEWATER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...
Nuvation Bio Inc. NUVB announced that the FDA has cleared its investigational new drug (IND) application to evaluate its pipeline candidate NUV-868., a BD2-selective oral small molecule bromodomain ...
BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, will present new in vivo data demonstrating its selective BRD4 (BD2) ...
(MENAFN- GlobeNewsWire - Nasdaq) BD2 opens its fourth round of Discovery Research funding for bipolar disorder with $18 million available. Washington, D.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Today, ...
Tiumbio Co Ltd. has described bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of cancer, fibrosis, diabetes, metabolic syndrome, and renal ...
Researchers from the Chinese Academy of Sciences evaluated the highly potent and selective inhibitor of the second bromodomain (BD2) of the bromodomain and extra-terminal (BET) family of proteins, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results